Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe

Pediatric Infectious Disease Journal

Volumn 32, Issue 8, 2013, Pages 856-862

  Musiime, Victor ^a   Cook, Adrian ^b   Bakeera Kitaka, Sabrina ^c,d   Vhembo, Tichaona ^e   Lutakome, Joseph ^f   Keishanyu, Rosette ^a   Prendergast, Andrew J ^b   Lubwama, Sam ^a   Robertson, Val ^e   Hughes, Peter ^f   Nathoo, Kusum ^e   Munderi, Paula ^f   Klein, Nigel ^g   Musoke, Philippa ^c,d   Gibb, Diana M ^b  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c MULAGO HOSPITAL   (Uganda)

^d MAKERERE UNIVERSITY   (Uganda)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^f UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Africa; bacteremia; children; HIV

Indexed keywords

ABACAVIR; AMIKACIN; AMOXICILLIN; AMPICILLIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; LAMIVUDINE; MEROPENEM; PENICILLIN G; ZIDOVUDINE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CORYNEBACTERIUM; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORAXELLA; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SALMONELLA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIAE; UGANDA; ZIMBABWE;

ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; BACTEREMIA; BACTERIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; UGANDA; ZIMBABWE;

EID: 84880617168     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31828c3991     Document Type: Article

References (47)

1. Bachou H, Tylleskär T, Kaddu-Mulindwa DH, et al. Bacteraemia among severely malnourished children infected and uninfected with the human immunodeficiency virus-1 in Kampala, Uganda. BMC Infect Dis. 2006;6:160.
2. Campo RE, Campo CE, Peter G, et al. Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era. AIDS Patient Care STDS. 2005;19:141-149.
3. Cohen C, Singh E, Wu HM, et al.; Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS-SA). Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS. 2010;24:1351-1360.
4. Karstaedt AS, Khoosal M, Crewe-Brown HH. Pneumococcal bacteremia during a decade in children in Soweto, South Africa. Pediatr Infect Dis J. 2000;19:454-457.
5. Nathoo KJ, Chigonde S, Nhembe M, et al. Community-acquired bacteremia in human immunodeficiency virus-infected children in Harare, Zimbabwe. Pediatr Infect Dis J. 1996;15:1092-1097.
6. Netsawang S, Punpanich W, Treeratweeraphong V, et al. Invasive pneumococcal infection in urban Thai children: a 10-year review. J Med Assoc Thai. 2010;93(suppl 5):S6-S12.
7. Noel F, Wright PF, Bois G, et al. Contribution of bacterial sepsis to morbidity in infants born to HIV-infected Haitian mothers. J Acquir Immune Defic Syndr. 2006;43:313-319.
8. Nyasulu P, Cohen C, De Gouveia L, et al. Increased risk of death in human immunodeficiency virus-infected children with Pneumococcal Meningitis in South Africa, 2003-2005. Pediatr Infect Dis J. 2011;30: 1075-1080.
9. Hatherill M. Sepsis predisposition in children with human immunodeficiency virus. Pediatr Crit Care Med. 2005;6(suppl 3):S92-S98.
10. Kapogiannis BG, Soe MM, Nesheim SR, et al. Trends in bacteremia in the pre-and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Pediatrics. 2008;121:e1229-e1239.
11. Steenhoff AP, Wood SM, Rutstein RM, et al. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006. Pediatr Infect Dis J. 2008;27:886-891
12. Le Roux DM, Cotton MF, le Roux SM, et al. Bacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa. Pediatr Infect Dis J. 2011;30:904-906.
13. Nunes MC, von Gottberg A, de Gouveia L, et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS. 2011;25:453-462.
14. Cotton MF, Wasserman E, Smit J, et al. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis. 2008;8:40.
15. Feikin DR, Jagero G, Aura B, et al. High rate of pneumococcal bacteremia in a prospective cohort of older children and adults in an area of high HIV prevalence in rural western Kenya. BMC Infect Dis. 2010;10:186.
16. Babirekere-Iriso E, Musoke P, Kekitiinwa A. Bacteraemia in severely malnourished children in an HIV-endemic setting. Ann Trop Paediatr. 2006;26:319-328.
17. BD. BD bactec instrumented blood culture systems. Available at: www.bd.com. Accessed September 19, 2011.
18. Turng BVM, Turner D, Pollitt J, et al. Detection of Extended Beta-lactamase among Enterobacteriaceae using Phoenix TM automated microbiology system with BDxpertTM system In: Interscience Conference on Antimicrobial agents and Chemotherapy (ICAAC). San Diego, CA; 2002. Available at: http://www.infectweb.com/only/nwsrpt15.htm. Accessed June 26, 2013.
19. CSLI. Clinical laboratory standards institute antimicrobial susceptibility testing. Available at: www.csli.org. Accessed September 19, 2011.
20. Smith PB, Tomfohrde KM, Rhoden DL, et al. API system: a multitube micromethod for identification of Enterobacteriaceae. Appl Microbiol. 1972;24:449-452.
21. Bauer AW, Kirby WM, Sherris JC, et al. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493-496
22. BSAC. BSAC susceptibility testing guide. Available at: bsac.org/uk. Accessed September 19, 2011.
23. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375:123-131.
24. Walker AS, Prendergast AJ, Mugyenyi P, et al.; DART and ARROW trial teams. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012;55:1707-1718.
25. Poon LM, Jin J, Chee YL, et al. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. Singapore Med J. 2012;53:720-725.
26. Aiken AM, Mturi N, Njuguna P, et al.; Kilifi Bacteraemia Surveillance Group. Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study. Lancet. 2011;378:2021-2027.
27. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis. 2005;191:2038-2045.
28. Jacobsen MC, Thiébaut R, Fisher C, et al. Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. J Infect Dis. 2008;198:481-485.
29. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314:1593-1599.
30. Klugman KP, Madhi SA, Huebner RE, et al.; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
31. Ministry of Health Uganda. UNEPI standards. First edition, 2003. Available at: http://www.basics.org/documents/pdf/UNEPI%20Standards.pdf. Accessed October 19, 2011.
32. WHO. Immunization profile-Zimbabwe. Available at: http://apps.who.int/ immunization-monitoring/en/globalsummary/countryprofileresult.cfm?C=zwe. Accessed October 19, 2011.
33. Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005;24:410-416.
34. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25:2451-2457.
35. Madhi SA, Klugman KP, Kuwanda L, et al. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIVinfected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009;199:1168-1176.
36. Madhi SA, Adrian P, Cotton MF, et al.; Comprehensive International Program of Research on AIDS 4 Study Team. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis. 2010;202: 355-361.
37. Lu CL, Hung CC, Chuang YC, et al. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother. 2013;9:398-404.
38. WHO. Antiretroviral therapy for HIV infection in infants and children; towards universal access: recommendations for a public health approach: 2010 revision [2010]. Available at: http://www.who.int/hiv/pub/paediatric/infants. Accessed September 30, 2011.
39. Gold-Standard. Azithromycin. Available at: http://www.answers.com/topic/ azithromycin-oral-suspension. Accessed March 26, 2012.
40. Dagan R, Barkai G, Leibovitz E, et al. Will reduction of antibiotic use reduce antibiotic resistance?: The pneumococcus paradigm. Pediatr Infect Dis J. 2006;25:981-986.
41. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis. 1997;24:356-362.
42. Chintu C, Bhat GJ, Walker AS, et al.; CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364:1865-1871.
43. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428-1434.
44. Sloos JH, Dijkshoorn L, van Boven CP. Septicaemias caused by a strain of Staphylococcus haemolyticus exhibiting intermediate susceptibility to teicoplanin in multiple intensive care unit patients. J Antimicrob Chemother. 2000;45:410-411.
45. Weinstein MP, Mirrett S, Van Pelt L, et al. Clinical importance of identifying coagulase-negative staphylococci isolated from blood cultures: evaluation of MicroScan Rapid and Dried Overnight Gram-Positive panels versus a conventional reference method. J Clin Microbiol. 1998;36:2089-2092.
46. WHO-Roll-back-Malaria. Malaria Endemic Countries. 2010.Available at: www.rbm.who.int/endemiccountries.html. Accessed December 2, 2012.
47. fitfortravel. Zimbabwe Malaria. Available at: http://www.fitfortravel. nhs.uk/destinations/africa/zimbabwe/zimbabwe-malaria-map.aspx. Accessed December 1, 2012.